DCGI approves India’s first COVID-19 vaccine candidate COVAXIN, human trials to begin in July

COVID-19 Vaccine: India’s first COVID 19 vaccine candidate COVAXIN has received the approval of the drug regulator DCGI for Phase 1 and Phase 2 human clinical trials. Human trials will begin in July, as reported by CNBC TV 18. This vaccine has been made by Bharat Biotech.

Bharat Biotech created the COVAXIN vaccine in collaboration with the Indian Council of Medical Research (ICMR) and the National Institute of Virology (NIV). Isolated SARS-CoV-2 strains were transferred to Bharat Biotech at NIV, Pune to manufacture the vaccine. At present, efforts are being made for the vaccine of Kovid 19 at this time. No one has been successful so far. However, some companies are in the final stages of human trials.

China’s military will use potential vaccine
On Monday, China’s military received approval to use a potential vaccine Ad5-nCoV of Kovid 19. This vaccine has been prepared by the Research Unit of the Military of China and CanSino Biologics. CanSino Biologics has stated that in clinical trials it has been proven that this candidate vaccine is safe. Ad5-nCoV is one of the 8 vaccine candidates created by Chinese companies and researchers who have been approved by Human Trials for the treatment of coronavirus-caused respiratory diseases.

CanSino said in a filing that China’s Central Military Commission approved on June 25 that China’s military could use the Ad5-nCoV vaccine for one year. This vaccine has been prepared by CanSino and Bi Jing Institute of Biotechnology in the Academy of Military Medical Sciences.

Written by 

Leave a Reply

Your email address will not be published. Required fields are marked *